{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:59:38Z","timestamp":1778309978060,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,6,24]],"date-time":"2009-06-24T00:00:00Z","timestamp":1245801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s11239-009-0367-6","type":"journal-article","created":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T04:58:30Z","timestamp":1245733110000},"page":"296-298","source":"Crossref","is-referenced-by-count":13,"title":["Modification of fibrin structure as a possible cause of thrombolytic resistance"],"prefix":"10.1007","volume":"29","author":[{"given":"Boguslaw","family":"Lipinski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,24]]},"reference":[{"key":"367_CR1","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1073\/pnas.78.7.4265","volume":"78","author":"SS Husain","year":"1981","unstructured":"Husain SS, Lipinski B, Gurewich V (1981) Rapid purification of a high-affinity plasminogen activator from human blood. Proc Natl Acad Sci USA 78:4265\u20134569","journal-title":"Proc Natl Acad Sci USA"},{"key":"367_CR2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1503\/cmaj.1041561","volume":"172","author":"MD Hill","year":"2005","unstructured":"Hill MD, Buchan AM (2005) Thrombolysis for acute ischemic stroke: results of the Canadian alteplase for stroke effectiveness study. CMAJ 172:1307\u20131312","journal-title":"CMAJ"},{"key":"367_CR3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2141.1993.tb08283.x","volume":"83","author":"CR Prentice","year":"1993","unstructured":"Prentice CR et al (1993) The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products. Br J Haematol 83:276\u2013281","journal-title":"Br J Haematol"},{"key":"367_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00365519909168323","volume":"230","author":"B Wiman","year":"1999","unstructured":"Wiman B (1999) Predictive value of fibrinolytic factors in coronary heart disease. Scan J Clin Lab Invest Suppl 230:23\u201331","journal-title":"Scan J Clin Lab Invest Suppl"},{"key":"367_CR5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF01921614","volume":"30","author":"B Lipinski","year":"1974","unstructured":"Lipinski B, Nowak A, Gurewich V (1974) Fibrinolysis versus fibrinogenolysis in man: resistance of fibrinogen to breakdown by fibrinolytic activity induced by venous occlusion. Experientia 30:84\u201385","journal-title":"Experientia"},{"key":"367_CR6","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood.V84.6.1874.1874","volume":"84","author":"C Steinmann","year":"1994","unstructured":"Steinmann C et al (1994) A new substitution, gamma 358 Ser\u2013>Cys, in fibrinogen Milano VII causes defective fibrin polymerization. Blood 84:1874\u20131880","journal-title":"Blood"},{"key":"367_CR7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1172\/JCI116371","volume":"91","author":"J Koopman","year":"1993","unstructured":"Koopman J et al (1993) Molecular basis for fibrinogen Dusart (Alpha 554Arg\u2013>Cys) associated with abnormal fibrinogen polymerization and thrombophilia. J Clin Invest 91:1637\u20131643","journal-title":"J Clin Invest"},{"key":"367_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF01886767","volume":"14","author":"B Lipinski","year":"1995","unstructured":"Lipinski B (1995) In vitro preparation and partial characterization of a novel complex of human fibrinogen with albumin. J Prot Chem 14:259\u2013262","journal-title":"J Prot Chem"},{"key":"367_CR9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.wad.0000213844.21001.a2","volume":"20","author":"B Lipinski","year":"2006","unstructured":"Lipinski B, Sajdel-Sulkowska E (2006) New insight into Alzheimer disease: demonstration of fibrin(ogen)-serum albumin insoluble deposits in brain tissue. Alzheimer Dis Assoc Disord 20:323\u2013326","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"367_CR10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1056-8727(01)00143-X","volume":"15","author":"B Lipinski","year":"2001","unstructured":"Lipinski B (2001) Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complic 15:203\u2013210","journal-title":"J Diabetes Complic"},{"key":"367_CR11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0049-3848(95)99613-D","volume":"78","author":"B Lipinski","year":"1995","unstructured":"Lipinski B, Federman AM, Krolewski AS (1995) Plasma macromolecular protein complex: Interaction with fibrin and fibrinolysis. Thromb Res 78:461\u2013465","journal-title":"Thromb Res"},{"key":"367_CR12","first-page":"61","volume":"27","author":"R Karpel","year":"1991","unstructured":"Karpel R, Marx G, Chevion M (1991) Free radical induced fibrinogen coagulation: modulation of neofibe formation by concentration, pH, and temperature. Isr J Med Sci 27:61\u201366","journal-title":"Isr J Med Sci"},{"key":"367_CR13","first-page":"149","volume-title":"Atherosclerosis: risk factors diagnosis and treatment","author":"B Lipinski","year":"2002","unstructured":"Lipinski B, Lipinska I (2002) Free radical-induced modification of human fibrinogen: implications for atherosclerosis. In: Kostner CM, Kostner KM (eds) Atherosclerosis: risk factors diagnosis and treatment. Monduzzi Editore, USA, pp 149\u2013152"},{"key":"367_CR14","doi-asserted-by":"crossref","first-page":"9908","DOI":"10.1016\/S0021-9258(18)48020-9","volume":"262","author":"KJA Davies","year":"1987","unstructured":"Davies KJA, Delsignore MA (1987) Protein damage and degradation by oxygen radicals. III. Modification of secondary and tertiary structure. J Biol Chem 262:9908\u20139913","journal-title":"J Biol Chem"},{"key":"367_CR15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1248\/cpb.34.1075","volume":"34","author":"H Inoue","year":"1986","unstructured":"Inoue H, Hirobe M (1986) Disulfide cleavage and insulin denaturation by active oxygen in copper(II)\/ascorbic acid system. Chem Pharm Bull 34:1075\u20131079","journal-title":"Chem Pharm Bull"},{"key":"367_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0891-5849(02)00837-7","volume":"33","author":"PA Szweda","year":"2002","unstructured":"Szweda PA, Friguet B, Szweda LI (2002) Proteolysis, free radicals and aging. Free Radic Biol Med 33:29\u201336","journal-title":"Free Radic Biol Med"},{"key":"367_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0005-2795(75)90130-0","volume":"400","author":"M Furlan","year":"1975","unstructured":"Furlan M, Kemp G, Beck EA (1975) Plasmic degradation of human fibrinogen. III. Molecular model of the plasmin-resistant disulfide knot in monomeric fragment D. Biochim Buiophys Acta 400:95\u2013111","journal-title":"Biochim Buiophys Acta"},{"key":"367_CR18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1079\/BJN2001435","volume":"87","author":"B Lipinski","year":"2002","unstructured":"Lipinski B (2002) Evidence in support of a concept of reductive stress. Br J Nutr 87:93\u201394","journal-title":"Br J Nutr"},{"key":"367_CR19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0891-5849(02)01006-7","volume":"32","author":"O Kakhlon","year":"2002","unstructured":"Kakhlon O, Cabantchik ZI (2002) The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med 32:1037\u20131046","journal-title":"Free Radic Biol Med"},{"key":"367_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mrfmmm.2003.08.004","volume":"531","author":"M Kruszewski","year":"2003","unstructured":"Kruszewski M (2003) Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res. 531:81\u201392","journal-title":"Mutat Res."},{"key":"367_CR21","first-page":"323","volume":"232","author":"GJ Brewer","year":"2007","unstructured":"Brewer GJ (2007) Iron and copper toxicity in disease of aging, particularly atherosclerosis and Alzheimer\u2019s disease. Exp Biol Med (Maywood) 232:323\u2013335","journal-title":"Exp Biol Med (Maywood)"},{"key":"367_CR22","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/01.CIR.103.23.2799","volume":"103","author":"SJ Duffy","year":"2001","unstructured":"Duffy SJ et al (2001) Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103:2799\u20132804","journal-title":"Circulation"},{"key":"367_CR23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/01.STR.0000251798.25803.e0","volume":"38","author":"M Millan","year":"2007","unstructured":"Millan M et al (2007) Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke 38:90\u201395","journal-title":"Stroke"},{"key":"367_CR24","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1161\/01.ATV.0000189303.45609.1f","volume":"25","author":"DE Ferrara","year":"2005","unstructured":"Ferrara DE, Taylor WR (2005) Iron chelation and vascular function: in search of the mechanism. Arterioscl Thromb Vasc Biol 25:2235\u20132237","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"367_CR25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1196\/annals.1345.071","volume":"1054","author":"JM Donovan","year":"2005","unstructured":"Donovan JM, Daugher R, Bree M, Marguis J (2005) Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann NY Acad Sci 1054:492\u2013494","journal-title":"Ann NY Acad Sci"},{"key":"367_CR26","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0891-5849(00)00403-2","volume":"29","author":"C Coudray","year":"2000","unstructured":"Coudray C, Favier A (2000) Determination of salicylate hydroxylation products as an in vivo oxidative stress marker. Free Radic Biol Med 29:1064\u20131070","journal-title":"Free Radic Biol Med"},{"key":"367_CR27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11239-006-6579-0","volume":"21","author":"IB Kovac","year":"2006","unstructured":"Kovac IB, Gorog DA, Yamamoto J (2006) Enhanced spontaneous thrombolysis: a new therapeutic challenge. J Thromb Thrombolysis 21:221\u2013227","journal-title":"J Thromb Thrombolysis"},{"key":"367_CR28","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ajh.20955","volume":"82","author":"SK Karmohapatra","year":"2007","unstructured":"Karmohapatra SK, Chakraborty K, Kahn NN, Sinha AK (2007) The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets. Am J Hematol 82:986\u2013995","journal-title":"Am J Hematol"},{"key":"367_CR29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14656560802636888","volume":"10","author":"JV Ly","year":"2009","unstructured":"Ly JV, Zavala JA, Donnan GA (2009) Neuroprotection and thrombolysis: combination therapy in acute ischemic stroke. Expert Opin Pharmacother 10:323\u2013331","journal-title":"Expert Opin Pharmacother"},{"key":"367_CR30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.brainresrev.2006.04.004","volume":"52","author":"TS Anekonda","year":"2006","unstructured":"Anekonda TS (2006) Resveratrol\u2014a boon for treating Alzheimer\u2019s disease? Brain Res Rev 52:316\u2013326","journal-title":"Brain Res Rev"},{"key":"367_CR31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.tiv.2005.03.003","volume":"19","author":"GM Campo","year":"2005","unstructured":"Campo GM et al (2005) Purified human plasma glycosaminoglycans limit oxidative injury by iron plus ascorbate in skin fibroblast cultures. Toxicology in Vitro 19:561\u2013572","journal-title":"Toxicology in Vitro"},{"key":"367_CR32","doi-asserted-by":"crossref","first-page":"483S","DOI":"10.1378\/chest.126.3_suppl.483S","volume":"126","author":"GW Albers","year":"2004","unstructured":"Albers GW et al (2004) Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 126:483S\u2013502S","journal-title":"Chest"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-009-0367-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-009-0367-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-009-0367-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T18:46:17Z","timestamp":1633632377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-009-0367-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,24]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1007\/s11239-009-0367-6","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,24]]}}}